List view / Grid view
Cell-based assays
New assay to detect genetic abnormalities in sarcomas
A new study describes an assay, anchored multiplex PCR (AMP)-based targeted next-generation-sequencing (NGS), with superior diagnostic utility compared to conventional techniques...
Mouse IgG type and Titer Kit
15 June 2018 | By IntelliCyt
The Intellicyt Mouse IgG Type and Titer Kit is a high throughput, multiplexed assay kit that enables analyses of isotype, titer and cell health in a single assay...
Application note: A novel way to expedite antibody discovery
Analyse isotype titer and cell health in one assay...
Streamlining drug discovery assays for cancer and cardiovascular disease
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
Expert view: How high-content platforms keep pace with the changing face of cell-based drug screening
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
Supporting the progression of phenotypic hits with bioactivity profiling
Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.
Whitepaper: Smart cell monitoring
This whitepaper outlines how advances in real-time live-cell monitoring and analysis methods are addressing these changing needs.
Using bioactivity profiling to support the progression of phenotypic hits
27 April 2018 | By Eurofins Pharma Discovery Services
In this webinar, we discussed a recent case study where a phenotypic screen was performed using poly I:C / IL-4 stimulated human bronchial epithelial cells. This resulted in the identification of 7 representative hits which provided starting points for new drug discovery opportunities.
in vitro phenotypic assays for Parkinson’s disease
26 April 2018 | By Charles River Laboratories
This webinar highlights cell based assays for Parkinson’s disease that include endpoints such as a-synuclein aggregation and mitophagy readouts.
Application note: CRISPR/Cas9 genome-edited cells express nanoBRET-donor that monitors protein interaction and trafficking
In this application note, BMG Labtech discuss how the Bioluminescence resonance energy transfer (BRET) is a versatile tool to study interactions and trafficking in proteins.
Expert view: Addressing the big challenges in cell-based assays
As the drug discovery industry takes on the complex disease states that plague our world, the need for more relevant and timely answers from cell-based assays has become a major challenge.
Expert view: Toward physiological relevance in drug discovery and development
Physiologically relevant screening models have become increasingly important in assay development and the screening of drug candidates.
Streamlining drug discovery assays for cancer and cardiovascular disease
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
Helpful B cells lend a hand to developing neurons
Researchers at Osaka University have identified an immune cell that promotes the growth of neuron-supporting cells in the developing mouse brain.